A randomized, open-label, Phase III study of obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B-Cell lymphoma: final analysis of GOYA

by Laurie H. Sehn, Maurizio Martelli, Marek Trněný, Wenxin Liu, Christopher R. Bolen, Andrea Knapp, Deniz Sahin, Gila Sellam, Umberto Vitolo
Published 2020-06-01